China available as an optional add-on for Prismaccess
Prioritis are pleased to announce that China is available as an optional add-on for Prismaccess. The data includes all reimbursed products...
11
Jul
06
Oct
New indications in oncology not easily accessible to French patients
A study conducted by Prioritis for G5 Santé and Leem has highlighted the difficult access of patients to recently approved...
19
Mar
UK Cancer Drugs Fund to be expanded for non-cancer therapies
The proposed ‘Innovative Medicines Fund’ extends the Cancer Drugs Fund (CDF) to include non-cancer diseases and is expected to be...
25
Feb
Japan’s First Pricing Reform Since 2013, expected in April 2021
Chuikyo, a key reimbursement policy panel of the Japanese Central Social Insurance Medical Council has approved the cost-effectiveness assessment (CEA)...
10
Feb
Cost-effectiveness and budget impact to be included in new IPTs
In Spain, The Ministry of Health announced that in 2021 the Therapeutic Positioning Reports (IPT) will be conducted under a...
20
Jan
Innovative CAR-T cell therapy set to be reimbursed by NICE
Tecartus (brexucabtagene autoleucel) is set to be reimbursed in England and Wales having received a recommendation for the Cancer Drugs...
14
Jan
New routes to marketing approval in Great Britain
As of 1st Jan 2021, Great Britain stopped following the EU centralised procedure for marketing authorisations. There are now many...
08
Jan
Best wishes from Prioritis
We hope this message finds you and your family in good health. The whole Prioritis team wishes you the very best...
12
Feb
EMA after Brexit? Prioritis continues to monitor the changes
The role of the EMA within the UK will continue until 31 December 2020. But the relationship remains uncertain from...
22
Oct
Prioritis at ISPOR Copenhagen stand C2-037
Prioritis has launched its PrismHEOR platforms reinforcing its unique offer of daily, intelligent and reliable published and upcoming data regarding...